Dorota Krochmalczyk

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 347 citations

Pharmacy, Hematology, Pharmacotherapy +5

A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs

Dorota Link-Lenczowska, Niels Pallisgaard, Sabrina Cordua et al. · Annals of Hematology · 2018 · 60 citations · Full text

Medicine, Molecular Medicine, Pathology +14

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Marta Sobas, Jean‐Jacques Kiladjian, Yan Beauverd et al. · Blood Advances · 2022 · 43 citations · Full text

Medicine, Hematology, Pediatrics +15

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · Blood · 2018 · 20 citations

Pharmacy, Hematology, Pharmacotherapy +6

Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study

Krzysztof Mądry, Karol Lis, Przemysław Biecek et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +17